May 7 (Reuters) - Regeneron Pharmaceuticals Inc said it expects sales of blockbuster eye drug Eylea to grow even more quickly following data that showed it was superior to rival treatments.
We plan to increase Regeneron ’s fair value estimate of $415 by ..... strong results were driven by U.S. Eylea sales and updated 2015 guidance of ..... first quarter of 2014. Revenue included Eylea U.S. sales of $541 million, up ..... driven by new DME patients. Ex-U.S. Eylea sales, as reported by partner Bayer ..... rheumatoid arthritis later this year and Regeneron plans on filing for approval by year-end
May 7 (Reuters) - Regeneron Pharmaceuticals Inc reported an 11 percent rise in quarterly profit, driven by surging demand for its top-selling eye drug, Eylea .
Americas - EMEA - APAC Key Vendors - Bayer AG - F. Hoffmann-La Roche Ltd. - Novartis AG - Pfizer Inc. - Regeneron Pharmaceuticals Inc . - Valeant Pharmaceuticals International Inc. Other Prominent Vendors - Abbott Laboratories Ltd. - Alcon
anti-VEGF treatments that require monthly injections (Roche's RHHBY Lucentis) and bimonthly injections ( Regeneron 's REGN Eylea ). We think the first DARPin molecule is likely to enter Phase III trials by 2016. Molecular Partners can earn
degeneration have been wildly successful, with Regeneron 's REGN and Bayer 's BAYRY Eylea and Novartis ' NVS and Roche 's RHHBY ..... We are relatively enthusiastic about Regeneron , as we expect Eylea 's dosing advantage and the addition of
increasing our fair value estimate for Regeneron to $383 per share from $365 following ..... of better-than-anticipated U.S. Eylea sales guidance of $2.17 billion ..... fourth quarter of 2013. Revenue included Eylea U.S. sales of $518 million, up 29 ..... that indication last year. Ex-U.S. Eylea sales, as reported by partner Bayer
Stefan Quenneville: Regeneron ( REGN ) is a biotechnology company ..... largely due to its key drug Eylea , which is a growing blockbuster ..... of biotechs fail here. But Regeneron has been able to do this successfully ..... really what's driving [ Regeneron 's] positive moat trend
maintaining our $365 fair value estimate for Regeneron after third-quarter results that were below expectations, with U.S. Eylea sales growing less than expected and ..... diabetic macular edema (DME) would allow Eylea sales to accelerate more rapidly into ..... recent superior top-line results of Eylea versus Lucentis and Avastin in a National
We are slightly raising Regeneron 's FVE to $365 per share (from ..... macular edema, which showed that Eylea demonstrated better efficacy and safety ..... patent infringement lawsuit against Regeneron /Sanofi’s PCSK9 drug, Alirocumab